President Trump’s widely-panned prescription drug pricing speech continues to earn poor reviews for choosing big drug companies over everyday Americans. The early reviews of the speech were not kind, with headlines ranging from “Looks Nothing Like What He Promised” to “Lets Drug Companies Off the Hook,” and they haven’t let up. As HHS Secretary Alex Azar attempts to cover the Administration’s tracks with his own speech this morning, here are some late-breaking headlines about Trump’s tone-deaf speech:

Washington Post: Trump’s drug price retreat adds to list of abandoned populist promises

Washington Post: The health industry appears unfazed by Trump’s drug pricing speech

Bloomberg: Drug Industry Dodges Its Worst Fears in Trump’s Plan to Lower Prices

Pittsburgh Post-Gazette: Experts say Trump’s prescription to reduce drug prices is not what the doctor ordered

PharmTech: Trump Drug Pricing Plan Outlines Rule Changes Pharma Can Live With

Fox News: Trump’s new prescription drug plan is incomplete — here are two ways to make it better

STAT News: Trump promised to bring pharma to justice. His speech sent drug stocks soaring

McKnight’s Long-Term Care News: Trump prescription plan doesn’t include Medicare-negotiated pricing

The American Prospect: To Bring Drug Prices Down, Trump Proposes — Nothing, Really

Fortune: Why Trump’s Big Drug Price Speech Sent Health Care Stocks Soaring